CFMG & Wellpath in California — a documentary investigation · Article 018 of 100 · Series 2 — Inside the management agreement

Assignment Asymmetry: Why the 2019 Transfer Matters Beyond Corporate History

Published

20 September 2026, 6:00 PM PT

Content last changed

20 September 2026, 6:00 PM PT

Public-evidence cutoff

20 September 2026, 6:00 PM PT

Sources checked

20 September 2026, 6:00 PM PT

Record through

20 September 2026, 6:00 PM PT

Editorial status

Public-source editorial review complete

Evidence note. This article relies on public records and distinguishes established fact, party position, allegation, judicial finding, inference and unresolved question. Nothing here is a finding that any identified corporation or individual violated California law unless a cited adjudicative source expressly says so.

Opening frame#

Assignment Asymmetry: Why the 2019 Transfer Matters Beyond Corporate History turns on the difference between authority written on paper and authority demonstrated in operation. The analysis reads the management-services architecture as a division of functions, then tests whether the economic and administrative structure supports, constrains, or leaves unanswered the professional authority formally reserved to CFMG.

The governing question is narrow: Could the manager move the relationship more easily than CFMG could? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

I. The Question and the Public Record#

The relevant public record is best read cumulatively. No single branding statement, county agenda item, corporate filing, bankruptcy disclosure, or management agreement resolves the entire relationship. The evidentiary value comes from comparing documents created for different purposes and asking whether they converge on the same allocation of identity, authority, economics, and professional responsibility.

Raymond herr — the longest documented post-founder president#

The public record supports a strong chronology for Herr:

• April 2015 — identified in Shepherd evidence as CFMG Chief Medical Officer and President.

• March 2017 — signs CFMG collective-bargaining agreement as President.

• December 2017 — signs Stanislaus contract as President.

• 2018 — identified by Alameda County as CFMG Chief Medical Officer and President.

• September 2018 — CDPH lists him as President and Chief Medical Officer.

• 2018 — signs Fresno CFMG agreement as President.

• 2020 — appears on Placer agreement as CFMG President.

• September 8, 2021 — signs Monterey Amendment No. 2 as CFMG President.

This is a substantial run of formal corporate/contractual evidence.

It gives Herr an unusually important place in the governance history because his tenure spans:

• the mature H.I.G./CMGC period;

• the 2018 CCS–CMGC combination;

• the creation of the Wellpath brand;

• the 2019 MSA assignment to Wellpath LLC.

The key unanswered question is:

What happened to the CFMG shareholder, board, and Company Designee structure during the 2018–2019 Wellpath transition while Herr was president?

The litigation record does not support a single consistent public position that:

“CFMG and Wellpath are always the same entity.”

Nor does it support the opposite proposition:

“CFMG and Wellpath operate as completely independent companies.”

Instead, the record shows a recurrent issue-dependent duality .

When formal corporate identity became dispositive after Chapter 11, parties repeatedly stipulated or acknowledged that CFMG was separate and distinct from Wellpath and had to be added as the actual or necessary professional-corporation defendant.

But in other litigation contexts—especially discovery, financial condition, records, employment administration, and institutional knowledge—the record shows substantial practical integration.

The most extreme example is Smith v. Santa Cruz County , where the parties stipulated, at CFMG’s request, that:

for purposes of that lawsuit, CFMG and Wellpath were for “all intents and purposes the same entity,” such that no distinction would be drawn between them.

In July 2026, the district court held CFMG to that stipulation in a punitive-damages/financial-discovery dispute and rejected CFMG’s attempt to narrow the stipulation after it had benefited from reduced discovery.

At the opposite end of the spectrum are post-bankruptcy cases such as Reynolds , Pugh , J.S. , Yang , Madrid , and Johnson , where the court record became more exact about CFMG being a distinct, nondebtor entity or actual contracting party.

Overfield supplies a third category: the corporate entities remain formally distinct, yet CFMG produced a Wellpath executive as its Rule 30(b)(6) witness about a CFMG physician termination, and that executive testified the physician was terminated by management working for Wellpath.

The litigation census therefore suggests a more defensible synthesis:

CFMG’s legal separateness is real, but the degree of functional integration with Wellpath has been sufficiently deep that CFMG itself has, in at least one case, accepted complete litigation interchangeability, while other cases expose shared HR, records, financial, risk, and management infrastructure. Bankruptcy made the formal boundary impossible to ignore and forced later cases to identify the professional corporation more precisely.

That is not alter-ego adjudication.

It is a documented history of shifting relevance of the corporate boundary.

II. Structural and Historical Context#

2019: the CFMG management agreement moves to Wellpath LLC#

The next public document is more precise.

Effective January 1, 2019, the parties executed an Assignment of Management Services Agreement .

The document identifies:

• California Forensic Medical Group, Inc. as the Company ;

• Wellpath LLC as the Manager ; and

• Wellpath Management, Inc., with its predecessor names, as the Outgoing Manager .

The assignment says the October 2018 corporate transaction made the entities affiliates and states that the MSA was being transferred to Wellpath LLC for efficiency in administering management functions. 2019 Assignment

That document is one of the clearest public markers of the transition into the Wellpath era.

It is also significant for another reason: the assignment states that the MSA was transferred together with related or incidental instruments, including relevant stock-transfer restriction agreements .

The assignment proves that such instruments were part of the transaction documents or related contractual architecture.

It does not reveal their operative terms.

That makes the underlying CFMG-specific stock-transfer and succession documents an important open-source target rather than a basis for speculation.

III. The Control and Governance Analysis#

Hiring and firing are also function-specific#

The Board’s guidance does not say every ordinary employment action involving a physician is necessarily the practice of medicine.

Its formulation focuses on selection, hiring and firing as related to clinical competency or proficiency .

That means an investigation of physician employment must ask why a decision was made.

A routine employment issue and a decision that a physician lacks clinical competence present different professional-control questions.

Enterprise consolidation#

2015–2017. Raymond Herr, M.D. becomes publicly visible as CFMG President/CMO and authorized official. Litigation and County records later connect him to finance, contracts, staffing, policies, LVN scope, and mortality-review evidence.

October 1, 2018. H.I.G. combines Correct Care Solutions and its CMGC platform, creating the enterprise that becomes Wellpath. This is an enterprise combination; it does not establish that the California professional corporation merged out of existence.

January 1, 2019. The CFMG MSA and related/incidental instruments are assigned to Wellpath LLC. The assignment expressly references relevant stock-transfer restriction agreements. This is the strongest CFMG-specific proof that ownership/succession instruments existed, but not proof of their contents.

Strongest evidence justifying further control investigation#

Conversely, several facts justify deeper investigation:

• The MSO is CFMG’s exclusive management-services provider.

• A management representative can attend and participate in CFMG equityholder/governance meetings, though without vote.

• CFMG physician employment forms are prepared by management and cannot be amended without management approval.

• The MSA assigns extensive physician HR functions to management.

• The MSA says management will determine physician base and incentive compensation .

• Management participates in staffing deliberations and schedule review.

• Wellpath publicly says it provides CFMG utilization-management functions.

• Management administers EMR systems and supervises storage/maintenance of patient records.

• Management negotiates client agreements and professional-service agreements on CFMG’s behalf.

• Management acquires/holds title to substantial equipment and recommends medical equipment.

• CFMG designated a Wellpath HR executive as Rule 30(b)(6) PMK about a CFMG physician termination.

• That witness testified the physician was terminated by management working for Wellpath.

• The Wellpath enterprise handbook is broad enough on its face to include entities managed by Wellpath LLC, while its exact application to CFMG physicians remains unresolved.

• Contemporaneous California operating records show Wellpath HR, clinical leadership, insurance, claims, and enterprise systems interacting directly with CFMG physician matters.

• The 2019 assignment transferred the MSA together with related stock-transfer restriction agreements into the Wellpath structure.

These facts do not establish illegality. They establish why approval and override evidence is essential.

The company-designee mechanism can concentrate CFMG corporate authority#

Section 1.4 of the MSA provides that when CFMG approval, consent, direction, or action is required, the action of the person designated as CFMG's Chief Executive Officer under its bylaws—the Company Designee —constitutes action of CFMG unless otherwise specified.

The management company may assume that required internal CFMG consents and approvals have been obtained.

This can be a commercially efficient agency mechanism.

But it can also become an evidentiary bottleneck.

If extensive CFMG corporate authority passed through one physician officer, the critical questions become:

• who held the Company Designee role each year;

• whether that person was a shareholder;

• whether that person held roles on the Wellpath/MSO side;

• what independent information the designee reviewed;

• whether board/shareholder deliberation occurred;

• whether the designee ever rejected management recommendations.

A structure can be formally physician-controlled while still concentrating all practical PC approval in one physician officer.

That is not automatically unlawful.

It does mean the independence of that office is central.

Assignment rights are asymmetric#

Section 9.7 contains one of the clearest contractual asymmetries in the MSA.

CFMG may not:

• assign the MSA;

• assign rights under the MSA;

• delegate duties under the MSA

without the management company's prior written consent.

The management company, by contrast, may freely:

• assign the agreement;

• assign its rights;

• delegate its duties

without CFMG's consent.

This asymmetry became concrete in 2019 when management rights moved to Wellpath LLC.

The 2019 Assignment states the management rights, responsibilities, obligations, duties, and related instruments—including relevant stock-transfer restriction agreements—were transferred to Wellpath LLC.

From a structural-control perspective, the question is:

Why could the manager change the entity occupying the management side without CFMG consent while CFMG itself could not transfer its contractual position without manager approval?

There may be benign commercial explanations.

But the provision increases the importance of determining:

• whether CFMG approved or separately ratified the 2019 transfer;

• whether CFMG received independent advice;

• whether any amendments accompanied the assignment;

• whether the stock-transfer restrictions changed at the same time.

Cfmg granted a security interest in all of its assets under exhibit d#

Exhibit D states that, as collateral for amounts CFMG owes the management company, CFMG grants the management company a security interest in and assignment of, to the extent permitted by law, all assets of CFMG then owned or created during the term , together with proceeds.

At the management company's request, CFMG is required to execute a UCC-1 financing statement reflecting that interest.

The management company is given Article 9 remedies upon specified breaches or a Credit Agreement Event of Default.

This is among the most important structural-control clauses in the MSA.

It should not be overstated.

Commercial creditors routinely take collateral.

A security interest is not equivalent to equity ownership.

But the breadth matters.

The investigation should determine:

• whether a UCC-1 was actually filed;

• current secured party;

• collateral description;

• continuations/amendments;

• whether professional receivables were included;

• whether equipment, bank accounts, contract rights, IP, or records were covered;

• whether remedies were ever threatened or exercised;

• whether post-2019 or post-bankruptcy amendments changed the secured party.

The central question is not "Did the MSO own CFMG?"

It is:

Could enforcement of the security interest deprive CFMG of the assets required to operate independently of the MSO?

Wellpath’s Chapter 11 case is the strongest natural experiment yet for testing the CFMG–Wellpath relationship.

The reason is straightforward.

Before bankruptcy, extensive operational integration could coexist with imprecise nomenclature because there was often little immediate reason for counties, clinicians, litigants, or courts to distinguish the professional corporation from the management enterprise with precision.

Bankruptcy changed that.

Once Wellpath entered Chapter 11:

• debtor and nondebtor status mattered;

• property of the estate mattered;

• executory-contract rights mattered;

• insurance and indemnity mattered;

• ownership and contract rights mattered;

• the identity of the professional corporations mattered;

• the ability to continue management relationships mattered;

• and the transition from H.I.G.-sponsored ownership to lender ownership mattered.

The bankruptcy record therefore forced Wellpath to explain its professional-corporation architecture in pleadings filed before a federal bankruptcy court.

The result is unusually revealing.

Wellpath’s own November 12, 2024 Professional Corporation Motion described the nationwide structure as a “friendly professional corporation” structure . The Debtors said the professional corporations were owned exclusively by licensed physicians affiliated with the Debtors , while the Debtors exercised certain control over the nonclinical business-management and administrative functions. At the same time, the Debtors disclosed that:

• the 18 professional corporations collectively generated more than $674 million in 2023 revenue “for the benefit of the Debtors” ;

• the Debtors and certain physician owners were parties to Stock Transfer Agreements restricting transfer of professional-corporation stock;

• those restrictions were intended not only to maintain state-law compliance and continuity of care but also to preserve the continuation of administrative services by the Debtors ;

• under those Stock Transfer Agreements, the Debtors had authority to ensure that the professional corporations remained duly licensed and qualified;

• in 2023 the Debtors remitted approximately $720 million to physician owners and vendors as professional-corporation operating costs;

• the Debtors collected certain professional-corporation receivables and deposited them into professional-corporation accounts;

• the Debtors considered the professional-corporation relationships indispensable to the success of their own reorganization.

Most strikingly, the same motion later said that the Debtors “maintain an interest in the Professional Corporations” and referred to revenue derived pursuant to the Debtors’ “ownership interests in the Professional Corporations.”

That latter language is facially difficult to reconcile with the same pleading’s statement that the professional corporations were owned exclusively by licensed physicians .

this record does not treat that wording as proof that Wellpath owned CFMG stock.

The phrase may reflect:

• imprecise bankruptcy advocacy;

• an economic or contractual “interest” rather than stock ownership;

• differences among the 18 professional corporations;

• or drafting shorthand that did not carefully distinguish equity from contractual rights.

The court did not conduct a trial determining that Wellpath owned CFMG.

But the wording is too important to ignore.

It creates one of the strongest internal-document contradictions found in this investigation and sharply increases the importance of the actual CFMG stock-transfer agreements.

The strongest current documentary reconstruction is that the CFMG management relationship did not require a new publicly filed post-bankruptcy assignment to move from the H.I.G.-era enterprise into reorganized Wellpath.

The more likely mechanism is simpler:

Wellpath LLC was already the manager under the January 1, 2019 assignment; it entered Chapter 11 as the contracting debtor; the CFMG MSA was still being described by Wellpath as operative during bankruptcy; the final Plan deemed all executory contracts assumed unless specifically rejected or otherwise excepted; no California Forensic Medical Group / CFMG MSA entry has been located in the reviewed rejection notices or final rejection schedule; the Confirmation Order made those assumptions effective without further court order; and the assumed contract re-vested in the applicable contracting Post-Restructuring Debtor.

That chain makes deemed assumption by Wellpath LLC on the May 9, 2025 Effective Date the best-supported explanation for continuity of the CFMG MSA.

This conclusion rests on five independent documentary points. First, the January 1, 2019 Assignment expressly made Wellpath LLC the “Manager” under the CFMG MSA. Second, as late as February 11, 2025, Wellpath’s own bankruptcy filing described CFMG as a professional corporation to which the Debtors provided managerial services pursuant to the January 2019 CFMG MSA . Third, Article V of the confirmed Plan provides that, on the Effective Date, all executory contracts are deemed assumed by the applicable Post-Restructuring Debtor unless they fall within stated exceptions. Fourth, the final Rejected Executory Contracts Schedule filed April 29, 2025 affirmatively rejects another professional-corporation relationship— Grand Prairie Healthcare PC —while no CFMG / California Forensic Medical Group entry has been located in the searchable final schedule. Fifth, a 2026 Sonoma County professional-services agreement again expressly identifies Wellpath LLC as the Management Services Organization providing administrative services to CFMG .

The conclusion requires one important qualification. The precise Docket 194 schedule row and proposed cure amount for the CFMG MSA have not yet been located in the searchable public corpus, and this investigation has not located any private post-emergence amendment or CFMG board ratification. Accordingly, the statement that the CFMG MSA was deemed assumed is a high-confidence documentary/legal inference , not a substitute for obtaining the exact contract register and cure schedule.

The january 1, 2019 assignment put Wellpath llc directly into the manager position#

The next essential instrument is the January 1, 2019 Assignment. It identifies CFMG as the “Company,” Wellpath LLC as the “Manager,” and Wellpath Management, Inc., formerly Correctional Medical Group Companies, Inc. / California Forensic Management Group, Inc., as the “Outgoing Manager.”

The assignment does not dissolve CFMG or replace it with Wellpath. Instead, it changes the party occupying the management side of the existing PC–MSO relationship. The outgoing manager irrevocably assigns the Management Services Agreement to Wellpath LLC together with related or incidental instruments, including relevant stock-transfer restriction agreements.

Primary source:

https://www.prisonlegalnews.org/media/publications/California\_Forensic\_Medical\_Group\_Assignment\_of\_Management\_Services\_Agreement.pdf

This creates the critical prepetition baseline:

CFMG professional corporation ↔ Wellpath LLC manager

not:

CFMG ↔ Wellpath Holdings.

That distinction becomes central in bankruptcy because the ultimate parent changed dramatically while Wellpath LLC itself remained the identified contracting manager .

Why CFMG consent may not have been contractually required#

The issue of CFMG consent requires special care.

the prior analysis identified an asymmetry in the 2012 MSA: CFMG could not assign its position without manager consent, while the management company had broad assignment rights.

But the 2025 restructuring may not even have constituted an assignment of the MSA from Wellpath LLC to another manager. If the contract remained with Wellpath LLC and only the upstream ownership changed, then the counterparty remained Wellpath LLC and a contractual assignment-consent provision may never have been triggered.

In addition, Article V neutralized change-of-control restrictions in assumed contracts to the maximum extent permitted by bankruptcy law.

Accordingly, the absence of a public CFMG consent document should not be treated as proof that Wellpath bypassed a contractual approval right.

The more significant governance question is different:

Even if CFMG approval was not legally required to preserve the contract, did its physician board independently evaluate whether continuing with the newly lender-owned manager remained in CFMG’s interests?

That is a corporate-governance and substantive-independence question, not simply a contract-assignment question.

Medical director authority — title is not enough#

The term “Medical Director” can conceal several legally different roles.

A physician may be:

• a site medical director for the Fresno County jail;

• a regional medical director;

• a national Wellpath physician executive;

• a CFMG officer or director;

• an MSO-employed physician providing management services;

• a member of a CFMG physician board;

• a credentialing or quality reviewer;

• or some combination of those roles.

the investigation must therefore stop treating “medical director” as a self-executing answer to control.

For every physician leader involved in a disputed event, the record should identify:

• employing entity;

• corporate office, if any;

• California license status;

• written appointment;

• written delegation;

• reporting line;

• scope of clinical authority;

• scope of HR authority;

• authority to bind CFMG;

• authority to approve or reject Wellpath recommendations;

• authority over privileging/credentialing;

• authority over peer review and section 805 reporting;

• authority over physician schedules and patient volume;

• authority over referral/utilization disputes;

• and evidence of actual exercise of those powers.

Dr. Dheeraj Taranath's April 2025 communication is especially relevant. He described Wellpath as the management services organization contracted to provide the “full range of administrative services” to CFMG and represented that matters raised by the physician had been reviewed with CFMG leadership and that Wellpath communications proceeded with CFMG leadership's knowledge and approval.

That communication supports two competing inferences.

Defense inference: Wellpath was operating as an MSO and took recommendations to CFMG leadership, which retained approval.

Investigative inference: Wellpath may have functioned as the practical decision engine, with CFMG leadership providing approval after recommendations had already been developed.

The distinction cannot be resolved from phrasing alone. The underlying approval records are needed.

B. The MSA creates structural dependence even while reserving professional judgment#

The control theory gives full credit to the MSA's professional-independence clauses.

Then it asks whether the rest of the architecture made independent exercise difficult in practice.

Potentially significant features identified in the investigation include:

• exclusive management;

• management participation in governance meetings;

• Company Designee mechanics;

• financial administration;

• bank-payment rights;

• broad security interests;

• staffing analysis;

• physician compensation administration;

• records and IT systems;

• employment-document administration;

• related stock-transfer restrictions referenced in assignment documents.

None independently proves CPOM.

Together they justify investigation of practical dependency.

IV. Contrary Evidence, Limits, and Competing Explanations#

A disciplined analysis must begin its limiting case with the strongest contrary evidence: The strongest contrary evidence is the MSA's explicit reservation of professional authority and real termination rights. The article must distinguish structural leverage from proof of an actual unlawful medical decision.

V. Missing Documents and Falsification Tests#

The record remains incomplete in material respects. Key unresolved points include Company Designee history, practical MSO replacement, compensation veto, and an actual event where formal professional authority changed management's preferred outcome.

2013: H.I.G. announces an investment#

On January 7, 2013, H.I.G. Capital announced that an affiliate had made a strategic investment in CFMG. H.I.G. described the transaction as a partnership with CFMG’s existing management team. H.I.G., 2013

The wording is important.

The public announcement supports an investment relationship. It does not, without the underlying stock records, establish exactly what entity H.I.G. acquired or whether a non-physician investor ever held CFMG professional-corporation shares.

That distinction should remain explicit throughout this investigation.

Layer ten: management fee, credit and collateral#

The filed agreement refers to:

• the management fee;

• a Deficit Funding Loan Agreement;

• broader credit relationships;

• and a security interest in company assets to the extent permitted by law.

The underlying financial documents are important because they may show the practical economic relationship between CFMG and the manager.

The MSA alone does not establish whether those mechanisms were ordinary commercial protections or whether they materially constrained CFMG’s ability to operate independently.

That is an open-document question.

The structural-control question#

The core structural question is not whether Wellpath legally owned CFMG.

The strongest currently available evidence cuts against that simplistic proposition.

In November 2024, Wellpath board co-chair Kip Hallman publicly stated that CFMG was a wholly separate entity, owned primarily by physicians, with no ownership overlap with Wellpath. Santa Barbara County later described CFMG as a separate physician-owned entity that used Wellpath to manage business aspects. CFMG remained a nondebtor professional corporation during the Wellpath Chapter 11 case.

Those facts are material.

But ownership of stock is only one form of control.

California's 2026 enforcement posture requires examination of whether a nonprofessional enterprise can exercise control through:

• contractual replacement rights;

• shareholder succession mechanisms;

• long-term exclusive management arrangements;

• financing;

• security interests;

• bank-account authority;

• control of assets or infrastructure;

• assignment rights;

• practical inability of the physician corporation to replace the manager.

The central the prior analysis inquiry therefore is:

Could CFMG physician owners independently reject, replace, or terminate Wellpath and continue operating a viable California medical corporation?

Current evidence supporting deeper structural-control investigation#

The strongest contrary or investigative facts include:

• Wellpath/MSO is the exclusive manager.

• The original term was ten years, with five-year automatic renewals.

• CFMG lacks an obvious broad termination-for-convenience right in the public MSA.

• Management receives notice of and can participate in all covered CFMG shareholder/Company Designee meetings.

• Failure to provide required meeting notice can support manager termination.

• CFMG action can be concentrated through one Company Designee.

• CFMG cannot assign the MSA without manager consent.

• Manager can freely assign without CFMG consent.

• The 2019 assignment transferred related stock-transfer restriction agreements.

• Management fee begins at 18% of adjusted gross revenue.

• Manager may cause disbursement from CFMG accounts, including advances before due date.

• CFMG grants a broad security interest in its assets to secure amounts owed.

• CFMG may be financially dependent on manager advances under the Deficit Funding Loan Agreement.

• Manager may terminate the MSA when the Deficit Funding Loan Agreement terminates.

• Certain termination scenarios accelerate management fees for the remainder of the term.

• Personnel restrictions may affect CFMG's ability to recreate management infrastructure after exit.

• Manager-side financing links the CFMG payment stream to collateral-agent arrangements.

• Current stock-transfer/succession instruments remain undisclosed in the public corpus.

These facts still do not establish unlawful control.

They establish why the missing instruments have unusually high evidentiary value.

After six volumes, the most important remaining structural question is ownership.

This article produces a significant clarification:

The public record now permits a reasonably strong reconstruction of CFMG's corporate officers and directors over time, but it still does not identify the current CFMG shareholders or their percentages with sufficient reliability.

That distinction is critical.

A person can be:

• a physician;

• an officer;

• a director;

• a president;

• a chief executive officer;

• a Company Designee under the MSA;

• a medical director;

• a Wellpath executive;

• and even the person signing CFMG contracts

without necessarily being a shareholder.

Conversely, a shareholder may hold no public operating title.

Accordingly, officer succession cannot be treated as proof of stock succession .

The strongest current governance evidence is:

• the 2012 MSA;

• county contracts signed under California corporate formalities;

• California Secretary of State Statements of Information;

• federal litigation;

• labor agreements;

• the Wellpath bankruptcy;

• Wellpath public corporate materials.

Those records establish who held many formal offices.

They do not disclose the stock ledger.

The stock-transfer restriction agreements expressly referenced in the 2019 assignment therefore remain the single most important missing ownership source.

Primary documents now required to complete the ownership chain#

The next document-production/retrieval priority is:

• CFMG stock ledger from 2012 to present.

• Every issued/cancelled stock certificate.

• Shareholder roster by year.

• Share percentages.

• CFMG shareholder agreements.

• Stock-transfer restriction agreements referenced in 2019 assignment.

• Buy-sell agreements.

• succession agreements.

• options.

• proxies.

• nominee/custodial agreements.

• death/disability succession provisions.

• license-loss succession provisions.

• employment-linked stock provisions.

• retirement/resignation transfers.

• board approvals of every stock transfer.

• shareholder approvals.

• valuations/purchase-price records.

• source of funds for each transfer.

• any MSO consent/veto rights.

• any security interest involving shares.

• all Company Designee appointments.

• bylaws from 2012 to present.

• articles/amendments.

• Statements of Information for every year available.

• board/director minutes.

• shareholder meeting minutes.

• written consents.

• conflict-of-interest policies.

• 2012 MSA approval resolutions.

• 2019 assignment approval resolutions.

• post-bankruptcy MSA ratification/continuation resolutions.

• 2026 Local Government–California authorization records.

Why bankruptcy is a true governance stress test#

The ordinary PC–MSO relationship asks whether a physician-owned professional corporation is genuinely independent while buying administrative support from a management company.

Chapter 11 adds a much harder question:

What does the physician corporation do when its exclusive manager becomes insolvent, enters Chapter 11, changes owners, and reorganizes the operating structure?

For an independent principal, that event should at least create the possibility of:

• evaluating the manager’s solvency;

• assessing contract breach/default rights;

• evaluating alternative managers;

• deciding whether to continue the MSA;

• reassessing management fees;

• obtaining independent legal advice;

• examining data/records continuity;

• considering malpractice and insurance continuity;

• evaluating effects on physician employment;

• approving any required assignment or post-emergence transition;

• and documenting the physician board’s judgment.

A decision to remain with Wellpath could be entirely rational.

The test is not whether CFMG changed managers.

The test is whether CFMG exercised an identifiable independent corporate choice .

To date, this investigation has not identified publicly filed CFMG board minutes, shareholder resolutions, independent-counsel memoranda, or other CFMG-specific governance records documenting such a decision.

That absence must be interpreted cautiously.

CFMG was a nondebtor professional corporation. Its internal board materials were not necessarily required to be filed in the Wellpath bankruptcy.

Thus the correct conclusion is not:

“CFMG’s board did nothing.”

The correct conclusion is:

The public bankruptcy record reviewed to date contains extensive evidence of what Wellpath’s Debtors sought to preserve in the PC relationships, but comparatively little public evidence of what CFMG’s physician board independently decided about continuing that relationship.

That asymmetry itself defines the next documentary inquiry.

The bankruptcy motion directly confirms stock-transfer agreements#

Before the bankruptcy review, the strongest evidence of CFMG stock-transfer restrictions came from the January 2019 assignment, which expressly transferred related instruments including “relevant stock transfer restriction agreements.”

Docket No. 15 materially strengthens that evidence at the enterprise level.

The Debtors disclosed that, in addition to PC Management Services Agreements, they and certain physician owners were parties to:

Stock Transfer Agreements

that:

• restrict transfer of a physician owner’s stock;

• facilitate a streamlined transition of ownership;

• promote compliance with state professional-entity requirements;

• address transfer events such as death and disability;

• promote continuity of care;

• and promote the continuation of administrative services by the Debtors .

The Debtors further stated:

Under the Stock Transfer Agreements, the Debtors have authority to ensure that the Professional Corporation is duly licensed and qualified.

This is one of the most important new findings in the entire record.

It establishes that stock-transfer arrangements were not merely passive restrictions designed to prevent transfer to an unlicensed person.

At least at the enterprise level, the Debtors themselves described the agreements as tools tied to:

• ownership transition;

• licensing continuity;

• and continuation of the Debtors’ management relationship.

That is precisely the type of contractual architecture California’s 2026 Art Center and Carbon Health enforcement developments make significant.

But a crucial limitation remains.

Docket No. 15 speaks generically about “certain PC Physicians.”

It does not publish the CFMG-specific Stock Transfer Agreement or state that every provision described applies identically to CFMG.

The CFMG connection is nevertheless stronger than a generic inference because the 2019 CFMG assignment independently confirms that relevant stock-transfer restriction agreements existed in the CFMG relationship .

The two sources therefore fit together:

2019 CFMG Assignment: CFMG-related stock-transfer restrictions existed and were assigned into the Wellpath structure.

2024 PC Motion: Wellpath explains the purposes and functions of Stock Transfer Agreements in its friendly-PC model generally.

The remaining question is the exact CFMG text.

ARTICLE V.F MAY CARRY RELATED AGREEMENTS WITH THE ASSUMED MSA, within limits#

Article V.F is especially interesting for the stock-control inquiry.

The Plan says that, unless otherwise provided, an assumed executory contract includes all modifications, amendments, supplements, restatements, or other agreements that in any manner affect the contract, together with related executory contracts and leases, rights, privileges, options, rights of first refusal, and other interests, unless those agreements were separately rejected.

Placed beside the January 2019 Assignment, which transferred the CFMG MSA together with related/incidental instruments including relevant stock-transfer restriction agreements, it creates a plausible legal pathway by which related instruments could continue with the assumed management relationship.

But the record must not jump too far. The current record does not establish that a particular CFMG Stock Transfer Agreement was itself executory, that Article V.F definitively assumed that exact document, that no separate treatment applied, or that every stock-control right survived unchanged.

The correct proposition is:

The Plan’s broad related-agreements provision makes continuation of MSA-linked instruments legally plausible and increases the importance of determining whether the CFMG stock-transfer agreement was separately scheduled, rejected, amended, or treated as an organizational document.

That remains a high-priority source question.

VI. Why the Issue Matters#

The stakes are practical rather than semantic. Counties need to know which entity is accountable for contracted performance; clinicians need to know where professional authority resides; courts and regulators need entity-specific evidence rather than brand shorthand; and the public needs a record that distinguishes corporate continuity from operational integration. Those distinctions become most important when the actors disagree, when a contract changes hands, when a professional decision conflicts with an economic preference, or when litigation requires a precise answer to who had authority to act.

VII. Falsification Tests and Evidentiary Limits Note#

The record does not support be read as establishing an unproven motive, an undisclosed shareholder, an unlawful medical override, or a legal conclusion that a court or regulator has not made. The strongest version of the thesis is the one that survives the missing-document test: identify the instrument, minutes, ledger, delegation, approval record, or disagreement event that would materially change the conclusion, then state what has and has not been found. If later primary evidence contradicts a proposition stated here, the correction should be made at the proposition level rather than defended through branding or organizational shorthand.

VIII. Related Articles#

• Article 017 — Deficit Funding, Security Interests, and the Economics of Saying No

• Article 019 — Could CFMG Actually Leave Wellpath? The Right-to-Leave Test

• Article 016 — The 18 Percent Question: What the Management Fee Says About Economic Integration

The proposition to be tested#

The central proposition in this article is not that every appearance of the Wellpath name proves control, nor that formal CFMG separateness ends the inquiry. The proposition to be tested is narrower: Could the manager move the relationship more easily than CFMG could? A serious legal brief should state that proposition before discussing motive, liability, or remedy because the same document can be highly probative on one dimension and nearly irrelevant on another.

For this subject, the principal evidentiary dimensions are assignment asymmetry, consent rights, manager mobility, and continuity. The source spine identified in the current public record is: MSA assignment clauses; 2019 assignment; Company consent requirements; post-bankruptcy continuity. Those sources should not be pooled as though they were interchangeable. A county contract speaks most reliably to the county's counterparty and purchased obligations. A management agreement speaks to contractual allocation between the professional corporation and manager. A court order speaks to the matter actually adjudicated. A party filing or corporate announcement remains a representation unless independently adopted or found by a tribunal.

A management-services agreement must be read function by function. Administrative delegation is not synonymous with delegation of professional judgment. The evidentiary task is to identify the exact contractual reservation, the exact management power, and the real-world implementation record when those provisions came into tension. The practical advantage of that method is that it prevents a common failure in complex-enterprise investigations: using a true fact about one relationship as proof of a different relationship. A shared brand may show integration; a W-2 may show payroll identity; a contract signature may show authority to bind a corporation; an officer title may show corporate office. None automatically proves stock ownership or final clinical authority.

The charging or enforcement threshold, if any regulator ever considered one, would therefore require an evidence chain rather than a collage: identify the protected or regulated function; identify the actor with formal authority; reconstruct the first operative decision; identify the person or entity that could approve, reject, modify, or reverse it; and verify who implemented the result. Until that chain is complete, the proper classification is evidence, inference, or unresolved question—not adjudicated fact.

Weighing the evidence#

The evidentiary hierarchy for Assignment Asymmetry: Why the 2019 Transfer Matters Beyond Corporate History should begin with contemporaneous primary instruments and end with retrospective shorthand. Executed contracts, amendments, assignments, board resolutions, authenticated corporate records, court orders, government payroll or labor records, and formal agency records ordinarily deserve more weight on the proposition they were created to establish than marketing language or later summaries. Even among primary materials, however, purpose matters. A contract can establish contractual rights without proving that those rights were exercised; a tax record can establish reporting without deciding every common-law employer factor; a bankruptcy schedule can establish debtor treatment without answering professional-governance questions for a nondebtor corporation.

The article's existing record illustrates why that hierarchy matters.ntiary lane. Assignment Asymmetry: Why the 2019 Transfer Matters Beyond Corporate History turns on the difference between authority written on paper and authority demonstrated in operation. The analysis reads the management-services architecture as a division of functions, then tests whether the economic and administrative structure supports, constrains, or leaves unanswered the professional authority formally reserved to CFMG.

A prosecutor, defense lawyer, regulator, or investigative editor should ask five questions of every source: Who created it? What legal or business purpose did it serve? What date and entity does it concern? Is the statement a recital, operative term, allegation, stipulation, finding, or marketing representation? What independent record could confirm or contradict it? Applying those questions consistently is more valuable than multiplying citations that all derive from the same underlying assertion.

This also defines how contradictions should be handled. When two records use different labels, the first step is not to accuse one of being false. The first step is to determine whether the records were answering different questions. Only after normalizing entity, date, capacity, forum, and purpose should a remaining contradiction be treated as substantive. That discipline makes the article stronger for both sides because it identifies where the record genuinely conflicts and where the conflict is merely semantic.

Chronology as a control test#

Chronology is often more probative than organizational charts. The decisive question is not merely who possessed authority on paper, but when a decision became operative and what happened immediately before and after that moment. A later board vote, HR notice, county communication, or litigation position may confirm, ratify, or explain an earlier act without proving who made the initial decision. Conversely, an early recommendation may have no legal effect until the authorized professional or contracting entity adopts it.

For Assignment Asymmetry: Why the 2019 Transfer Matters Beyond Corporate History, the chronology should be reconstructed with document-level precision. Investigators should place each significant contract, amendment, email that has entered the public record, board action, personnel or agency event that is lawfully publishable, and court filing on a single timeline. Each entry should identify the actor, capacity, entity, action verb, and legal effect. Terms such as “recommended,” “approved,” “directed,” “implemented,” “ratified,” “reported,” and “terminated” are not synonyms. The wording can reveal whether a participant supplied information, exercised discretion, or merely carried out another actor's decision.

The current article supplies anchor points that should remain central. The governing question is narrow: Could the manager move the relationship more easily than CFMG could? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material. What happened to the CFMG shareholder, board, and Company Designee structure during the 2018–2019 Wellpath transition while Herr was president?

A robust chronology is also the best protection against overstatement. If the alleged controlling act occurred before the supposedly controlling actor entered the process, that theory weakens. If a professional body acted only after implementation, a claim that it supplied the first operative decision requires qualification. If the public record shows independent deliberation before implementation, that evidence materially strengthens the formal-independence account. The analysis therefore must treat time as an evidentiary variable, not just background narrative.

Sources and authorities#

1. 2019 Assignment www.prisonlegalnews.org — https://www.prisonlegalnews.org/media/publications/California\_Forensic\_Medical\_Group\_Assignment\_of\_Management\_Services\_Agreement.pdf
2. H.I.G., 2013 hig.com — https://hig.com/news/h-i-g-capital-announces-strategic-investment-in-california-forensic-medical-group/